A Multisite Phase IB Study of Pevonedistat, Azacitidine and Venetoclax (PAVE) for the Treatment of Subjects with Acute Myelogenous Leukemia (AML)

Protocol No
IIT-ATALLAH-PAVE-AML
Principal Investigator
Ehab Atallah
Phase
I
Summary
In this study, we want to determine the safety of the combination of pevonedistat, azacitidine and venetoclax for acute myelogenous leukemia. We will also evaluate how well this combination works in patients with AML. Everyone in this study will receive pevonedistat, azacitidine and venetoclax.
Description
The study hypothesis is that the combination of pevonedistat, azacitidine, and venetoclax will be effective, safe, and well tolerated in patients with AML.
Participating Institutions
Froedtert Hospital
Status
OPEN TO ACCRUAL
Share This: